These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35203384)

  • 1. A Transcriptional Link between HER2, JAM-A and FOXA1 in Breast Cancer.
    Cruz RGB; Madden SF; Brennan K; Hopkins AM
    Cells; 2022 Feb; 11(4):. PubMed ID: 35203384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human Epidermal Growth Factor Receptor-3 Expression Is Regulated at Transcriptional Level in Breast Cancer Settings by Junctional Adhesion Molecule-A via a Pathway Involving Beta-Catenin and FOXA1.
    Cruz RGB; Madden SF; Richards CE; Vellanki SH; Jahns H; Hudson L; Fay J; O'Farrell N; Sheehan K; Jirström K; Brennan K; Hopkins AM
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33669586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Junctional adhesion molecule-A is co-expressed with HER2 in breast tumors and acts as a novel regulator of HER2 protein degradation and signaling.
    Brennan K; McSherry EA; Hudson L; Kay EW; Hill AD; Young LS; Hopkins AM
    Oncogene; 2013 May; 32(22):2799-804. PubMed ID: 22751120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural compound Tetrocarcin-A downregulates Junctional Adhesion Molecule-A in conjunction with HER2 and inhibitor of apoptosis proteins and inhibits tumor cell growth.
    Vellanki SH; Cruz RGB; Jahns H; Hudson L; Sette G; Eramo A; Hopkins AM
    Cancer Lett; 2019 Jan; 440-441():23-34. PubMed ID: 30312728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transforming growth factor-β1 attenuates junctional adhesion molecule-A and contributes to breast cancer cell invasion.
    Wang Y; Lui WY
    Eur J Cancer; 2012 Dec; 48(18):3475-87. PubMed ID: 22647687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Taketani K; Aishima S; Oda Y; Morita M; Maehara Y
    Breast Cancer; 2015 Sep; 22(5):520-8. PubMed ID: 24415069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Breast cancer cell migration is regulated through junctional adhesion molecule-A-mediated activation of Rap1 GTPase.
    McSherry EA; Brennan K; Hudson L; Hill AD; Hopkins AM
    Breast Cancer Res; 2011 Mar; 13(2):R31. PubMed ID: 21429211
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of junctional adhesion molecule-A expression induces cell apoptosis and reduces breast cancer progression.
    Murakami M; Giampietro C; Giannotta M; Corada M; Torselli I; Orsenigo F; Cocito A; d'Ario G; Mazzarol G; Confalonieri S; Di Fiore PP; Dejana E
    PLoS One; 2011; 6(6):e21242. PubMed ID: 21695058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases.
    Horimoto Y; Arakawa A; Harada-Shoji N; Sonoue H; Yoshida Y; Himuro T; Igari F; Tokuda E; Mamat O; Tanabe M; Hino O; Saito M
    Br J Cancer; 2015 Jan; 112(2):345-51. PubMed ID: 25422910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of lineage-specific epigenetic regulators FOXA1 and GRHL2 through chromatin accessibility profiling in breast cancer cell lines.
    Yang L; Kumegawa K; Saeki S; Nakadai T; Maruyama R
    Cancer Gene Ther; 2024 May; 31(5):736-745. PubMed ID: 38429368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen receptor and FOXA1 coexpression define a "luminal-AR" subtype of feline mammary carcinomas, spontaneous models of breast cancer.
    Dagher E; Royer V; Buchet P; Abadie J; Loussouarn D; Campone M; Nguyen F
    BMC Cancer; 2019 Dec; 19(1):1267. PubMed ID: 31888566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion.
    Naik MU; Naik TU; Suckow AT; Duncan MK; Naik UP
    Cancer Res; 2008 Apr; 68(7):2194-203. PubMed ID: 18381425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High FOXA1 protein expression might predict late recurrence in patients with estrogen-positive and HER2-negative breast cancer.
    Horimoto Y; Sasahara N; Sasaki R; Hlaing MT; Sakaguchi A; Saeki H; Arakawa A; Himuro T; Saito M
    Breast Cancer Res Treat; 2020 Aug; 183(1):41-48. PubMed ID: 32572714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LncRNA DSCAM-AS1 interacts with YBX1 to promote cancer progression by forming a positive feedback loop that activates FOXA1 transcription network.
    Zhang Y; Huang YX; Wang DL; Yang B; Yan HY; Lin LH; Li Y; Chen J; Xie LM; Huang YS; Liao JY; Hu KS; He JH; Saw PE; Xu X; Yin D
    Theranostics; 2020; 10(23):10823-10837. PubMed ID: 32929382
    [No Abstract]   [Full Text] [Related]  

  • 16. Development of a Novel Weighted Ranking Method for Immunohistochemical Quantification of a Heterogeneously Expressed Protein in Gastro-Esophageal Cancers.
    Richards CE; Sheehan KM; Kay EW; Hedner C; Borg D; Fay J; O'Grady A; Hill ADK; Jirström K; Hopkins AM
    Cancers (Basel); 2021 Mar; 13(6):. PubMed ID: 33805812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of FOXA1 expression on the prognosis of patients with hormone receptor-positive breast cancer.
    Hisamatsu Y; Tokunaga E; Yamashita N; Akiyoshi S; Okada S; Nakashima Y; Aishima S; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Apr; 19(4):1145-52. PubMed ID: 21984487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multilayered proteomics reveals that JAM-A promotes breast cancer progression via regulation of amino acid transporter LAT1.
    Magara K; Takasawa A; Takasawa K; Aoyama T; Ota M; Kyuno D; Ono Y; Murakami T; Yamamoto S; Nakamori Y; Nakahashi N; Kutomi G; Takemasa I; Hasegawa T; Osanai M
    Cancer Sci; 2024 Sep; 115(9):3153-3168. PubMed ID: 38943512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell lineage tracing links ERα loss in Erbb2-positive breast cancers to the arising of a highly aggressive breast cancer subtype.
    Ding Y; Liu Y; Lee DK; Tong Z; Yu X; Li Y; Xu Y; Lanz RB; O'Malley BW; Xu J
    Proc Natl Acad Sci U S A; 2021 May; 118(21):. PubMed ID: 34006643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAM-A Acts via C/EBP-α to Promote Claudin-5 Expression and Enhance Endothelial Barrier Function.
    Kakogiannos N; Ferrari L; Giampietro C; Scalise AA; Maderna C; Ravà M; Taddei A; Lampugnani MG; Pisati F; Malinverno M; Martini E; Costa I; Lupia M; Cavallaro U; Beznoussenko GV; Mironov AA; Fernandes B; Rudini N; Dejana E; Giannotta M
    Circ Res; 2020 Sep; 127(8):1056-1073. PubMed ID: 32673519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.